4-AcO-DET

Discovery

4-AcO-DET was synthesized in 1958 by Albert Hofmann at Sandoz Laboratories in Basel,^[2] as part of a systematic exploration of psilocybin-related tryptamine esters. Hofmann and Franz Troxler also synthesized the active metabolite 4-HO-DET (ethocin/CZ-74) and a phosphorylated structural analog, CEY-19^[6] — both intended as shorter-acting alternatives to psilocybin for clinical use.

Clinical use

CZ-74 entered psycholytic therapy — the European model of psychedelic-assisted psychotherapy — during the 1960s.^[3] Hanscarl Leuner deployed it across approximately 30 treatment centers; clinical reports described CZ-74 as producing virtually no side-effects at therapeutic doses.^[7] Alexander and Ann Shulgin later documented both 4-HO-DET and its acetate ester in TiHKAL (1997), noting faster onset and greater potency than a simple prodrug would explain.^[8]

Modern era

4-AcO-DET appeared on the research chemical market in May 2001, sold as ethacetin or ethylacybin.^[4] Its parent compound DET is Schedule I under both the UN 1971 Convention and US federal law,^[9] but 4-AcO-DET remains unscheduled in most countries. A 2022 DEA proposal to schedule related tryptamines was ultimately withdrawn,^[10] though regulatory attention to this structural class continues.

Structural class

4-AcO-DET belongs to the 4-substituted tryptamine family, which includes psilocybin, psilocin, and 4-AcO-DMT. The acetoxy group at the 4-position of the indole ring makes it a prodrug: the body strips the acetate group to yield 4-HO-DET (CZ-74), the pharmacologically active form.^[1] The N,N-diethyl substitution places it between the smaller dimethyl group of psilocin and larger diisopropyl variants in terms of molecular bulk.^[11]

Molecular properties

The molecular formula is C₁₆H₂₂N₂O₂ (274.36 g/mol).^[12] In freebase form, the compound is chemically unstable, degrading on exposure to air, light, and moisture.^[4] Degraded samples contain 4-HO-DET plus two unidentified compounds of unknown toxicity.^[4] Salt form and airtight frozen storage with desiccant may extend shelf life.^[4]

Mechanism of action

4-AcO-DET is believed to act as a prodrug.^[4][1] Enzymes in the blood break it down into 4-HO-DET (CZ-74), the pharmacologically active compound — the same conversion observed in degraded samples.^[4] This mirrors how psilocybin converts into psilocin.

4-HO-DET activates serotonin receptors — the primary target of all tryptamine psychedelics. No binding data specific to this compound have been published,safety citation needed but class-level research confirms strong serotonin receptor affinity for 4-substituted tryptamines.^[11][13] Shulgin observed faster onset and greater potency than prodrug conversion alone would predict,^[8] suggesting the intact compound may also act directly on receptors.

Pharmacokinetics

No human pharmacokinetic data exist for 4-AcO-DET.safety citation needed The active metabolite 4-HO-DET is expected to be broken down by liver enzymes, with monoamine oxidase playing a secondary role — by analogy to Psilocin.^[14] Acetoxy prodrugs may activate more slowly or incompletely than phosphate ester prodrugs like psilocybin.^[1]

Where it acts

As a serotonin receptor activator (via its metabolite 4-HO-DET), 4-AcO-DET is expected to act on the same brain circuits documented for other serotonergic psychedelics. No neuroimaging data exist for this compound. In studies of psilocybin and LSD, serotonin receptor activation disrupts the brain's default mode network — the system that maintains the ongoing sense of self — while increasing communication between regions that normally work in isolation.

This disruption produces greater complexity in neural signaling and weakens the brain's filtering of sensory input. Visual distortions arise from disrupted sensory gating, altered self-perception from default mode dissolution, and novel thought patterns from increased cross-network connectivity.

Why it matters

The leading theoretical framework proposes that psychedelics reduce the brain's confidence in its existing models of reality, allowing raw sensory and emotional input to carry greater weight.citation needed Separately, serotonergic psychedelics may promote new neural connections through signaling cascades involving growth factor receptors.^[15] Whether 4-AcO-DET engages these neuroplasticity pathways with meaningful potency is unknown.

Toxicity

No lethal dose data exist for 4-AcO-DET in any species, and no case reports of overdose or death attributable to the compound have been published.^[16][17] This absence likely reflects limited detection: tryptamines are not part of standard toxicology panels, so their contribution to drug-related emergencies may be significantly underestimated.^[17]

Psychological risks

Acute risks include anxiety, panic, paranoia, and dysphoria. At high doses, thought loops, ego dissolution, and depersonalization can become severely distressing.

Prolonged psychotic episodes have been documented in people with personal or family history of psychotic disorders or bipolar disorder using serotonergic psychedelics. Persistent visual disturbances after use — a condition known as HPPD — have been reported with tryptamine psychedelics, though reliable prevalence estimates do not exist. No published adverse event data specific to 4-AcO-DET exist.safety citation needed

Tolerance and dependence

4-AcO-DET is not habit-forming. Tolerance builds rapidly — even after a single dose — because serotonin receptors in the frontal cortex downregulate in response.^[5] The same mechanism that reduces sensitivity also removes the drive to redose, making compulsive use pharmacologically self-limiting.

Tolerance is estimated to halve over roughly 3 days and fully reset at approximately 7 days. It extends to other serotonergic psychedelics including psilocybin, LSD, and DMT. Related tryptamines show low reinforcement and low abuse liability in animal studies.^[18]

Drug interactions

The main hazard is combining 4-AcO-DET with drugs that raise serotonin levels. The active metabolite 4-HO-DET acts on the serotonin system and may also affect the SERT,^[19] creating multiple pathways for serotonin overload in combination.

Tramadol poses the most clearly documented danger. It blocks serotonin reuptake^[20][21] and is among the opioids most associated with serotonin syndrome^[20] — a potentially fatal overheating and seizure response. Case reports confirm severe, prolonged serotonin toxicity from this combination.^[22][21]

MAOIs block the enzyme that breaks down 4-HO-DET, dramatically amplifying effects in dangerous and unpredictable ways.^[14] SSRIs and SNRIs may alter or intensify effects, with serotonin syndrome risk at higher doses. Lithium has been linked to seizures and heart rhythm disturbances when combined with serotonergic psychedelics.safety citation needed Cannabis may intensify effects and raise anxiety through non-serotonin mechanisms.

Contraindications

No substance-specific contraindication data exist for 4-AcO-DET. The following are inferred from serotonin receptor agonist pharmacology and class-level evidence.safety citation needed

Absolute contraindications:

• Personal or family history of psychotic disorders or schizophrenia — serotonin receptor activation may trigger or worsen psychotic episodes, the most consistently documented psychiatric risk across serotonergic psychedelics.
• Concurrent MAOI therapy — risk of dangerous and unpredictable serotonergic potentiation.
• Concurrent lithium therapy — seizure and heart rhythm disturbance risk documented for the psychedelic class.

Relative contraindications:

• Bipolar disorder — risk of triggering manic episodes.
• Concurrent SSRI/SNRI therapy — altered and unpredictable effects; serotonin syndrome risk at higher doses.
• Heart conditions — increased heart rate and blood pressure are reported for the serotonergic psychedelic class.
• Pregnancy and nursing — no safety data exist; serotonergic psychedelics are contraindicated due to unknown effects on fetal development.

4-AcO-DET occupies an ambiguous legal position in most jurisdictions — its parent compound DET is internationally controlled, but 4-AcO-DET itself is not separately listed in any international convention.^[9]

Analog and prodrug considerations

The Federal Analog Act potentially captures 4-AcO-DET as a substantially similar compound to DET when intended for human consumption. Its dual status as both a structural analog of a scheduled substance and a prodrug for an unscheduled active tryptamine creates layered legal complexity. The DEA's 2022 proposed rule, though withdrawn, signals continued regulatory attention to this structural class.^[10]